Therefore, the authors concluded that HIPK2 protein expression is associated with chemo-response in early-stage colon cancer, which represents an initial step toward defying a novel predictive marker for patients with stage II colon cancer who may benefit from adjuvant therapy [71]. This evidence concerns the gene HIPK2 and malignant colon neoplasm.